

BCBe/04/Neb-Car/082

Comparison of the effects of combined rate and rhythm control treatment with Nebivolol and electric cardioversion to rate-control treatment with Nebivolol alone on clinical and echocardiographic parameters in patients with Left ventricular dysfunction induced tachycardia

This study has been completed. Results will be soon available in the "Results section"

Sponsor: Berlin Chemie AG

Intervention: Nebivolol 5 mg

Study type & design: Parallel groups, randomized phase III study

Main criteria for inclusion: Patients with Hypertension 18-65 y.o. with newly occurring supraventricular tachycardia with a heart rate >140 bpm within the last three months and Ejection fraction <50% after i.v. rate control treatment with metoprolol and/or digitalis i.v.

Main criteria for exclusion: Acute MI, Valve disorders, Hyperthyroidism, Contraindication to Heparin Concomitant treatment with antiarrhythmics and other beta blockers except nebivolol Female of childbearing potential without adequate contraception Pregnancy or lactation Psychiatric diseases, history of alcohol and/or drug abuse Patients who are currently participating in another clinical trial or who have received an investigational drug within 30 days prior entering the study Patients who are unwilling or unable to provide informed consent